ALK NSCLC treatment, ‘Zykadia’ will be applied for insurance benefit
As approved in the health insurance benefit, another ALK(Anaplastic Lymphoma Kinase) positive non-small cell lung cancer treatment can now be clinically used.
In the ‘Announced Amendment on Drugs Prescribed for Cancer Patients’ recently revealed by the Health Insurance Review & Assessment Servic...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.